During the past decade, Universitätsklinikum Essen; Zentrum Für Frauenheilkunde conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 9 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "MedSIR" with 2 trials sponsored, "AGO Study Group" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde" #1 collaborator was "German Breast Group" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde" are "Breast Cancer" (5 trials), "Ovarian Cancer" (3 trials), "Breast Neoplasms" (2 trials), "Advanced Breast Cancer" (1 trials) and "Carcinosarcoma" (1 trials). Many other conditions were trialed in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde" are "Drug" (16 trials). Other intervention types were less common.

The name of intervention was led by "Pertuzumab" (4 trials), "Placebo" (4 trials), "Trastuzumab" (3 trials), "Bevacizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde" are 9 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Universitätsklinikum Essen; Zentrum Für Frauenheilkunde". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".